Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb Co's Ending Cash Position for the quarter that ended in Mar. 2026 was CHF7,545 Mil.
Bristol-Myers Squibb Co's quarterly Ending Cash Position
declined
from Sep. 2025 (CHF12,519 Mil) to Dec. 2025 (CHF8,143 Mil) and
declined
from Dec. 2025 (CHF8,143 Mil) to Mar. 2026 (CHF7,545 Mil).
Bristol-Myers Squibb Co's annual Ending Cash Position
declined
from Dec. 2023 (CHF9,962 Mil) to Dec. 2024 (CHF9,225 Mil) and
declined
from Dec. 2024 (CHF9,225 Mil) to Dec. 2025 (CHF8,143 Mil).
Bristol-Myers Squibb Co Ending Cash Position Related Terms
Bristol-Myers Squibb Co Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Bristol-Myers Squibb Co's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Ending Cash Position Chart
Bristol-Myers Squibb Co Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Bristol-Myers Squibb Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of CHF7,545 Mil mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Ending Cash Position of CHF7,545 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Ending Cash Position too high?
Bristol-Myers Squibb Co's current Ending Cash Position is CHF7,545 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Ending Cash Position compare to PFE and GILD?
Bristol-Myers Squibb Co's Ending Cash Position of CHF7,545 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Ending Cash Position is CHF7,545 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Ending Cash Position of CHF7,545 Mil. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current Ending Cash Position is CHF7,545 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Ending Cash Position is CHF7,545 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.
Key valuation signals for XSWX:BMY:
Ending Cash Position: CHF7,545 Mil
GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score
Get the complete analysis for XSWX:BMY
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
